Several studies have suggested that PDE5 and cGMP signaling pathways can be considered as new candidates for discovering novel therapeutic strategies toward treating breast cancer, especially triple-negative subtype[12,18,19]. The gene discussed is PDE5A; the disease is breast carcinoma.